Vaccine-Induced Immune Thrombotic Thrombocytopenia with Disseminated Intravascular Coagulation and Death following the ChAdOx1 nCoV-19 Vaccine
Journal of Stroke and Cerebrovascular Diseases, ISSN: 1052-3057, Vol: 30, Issue: 9, Page: 105938
2021
- 34Citations
- 91Captures
- 7Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations34
- Citation Indexes31
- 31
- CrossRef22
- Policy Citations3
- Policy Citation3
- Captures91
- Readers91
- 91
- Mentions7
- Blog Mentions4
- Blog4
- News Mentions3
- News3
Most Recent News
COVID-19 Vaccines: Proof of Lethality. Over One Thousand Scientific Studies
All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version). To receive Global Research’s Daily Newsletter (selected articles), click here. Visit … The post COVID-19 Vaccines: Proof of Lethality. Over One Thousand Scientific Studies appeared first on Global Research.
Case Description
Coronavirus is a novel human pathogen causing fulminant respiratory syndrome (COVID-19). Although COVID-19 is primarily a disease of the lungs with florid respiratory manifestations, there are increasing reports of cardiovascular, musculoskeletal, gastrointestinal, and thromboembolic complications. Developing an effective and reliable vaccine was emergently pursued to control the catastrophic spread of the global pandemic. We report a fatal case of vaccine-induced immune thrombotic thrombocytopenia (VITT) after receiving the first dose of the ChAdOx1 nCoV-19 vaccine. We attribute this fatal thrombotic condition to the vaccine due to the remarkable temporal relationship. The proposed mechanism of VITT is production of rogue antibodies against platelet factor-4 resulting in massive platelet aggregation. Healthcare providers should be aware of the possibility of such fatal complication, and the vaccine recipients should be warned about the symptoms of VITT.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1052305721003414; http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2021.105938; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85108341629&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/34171649; https://linkinghub.elsevier.com/retrieve/pii/S1052305721003414; https://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2021.105938
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know